Crossmark

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Crossref DOI link: https://doi.org/10.1186/s12962-023-00473-5

Published Online: 2023-09-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Zi-Rong https://orcid.org/0000-0002-4777-6792
Chueh, Chen-Han https://orcid.org/0000-0002-3337-2586
Chiang, Nai-Jung https://orcid.org/0000-0001-9292-0055
Tsai, Yi-Wen https://orcid.org/0000-0003-1422-7217
License Information

Text and Data Mining valid from 2023-09-11

Version of Record valid from 2023-09-11
More Information

Article History

Received: 7 April 2023

Accepted: 28 August 2023

First Online: 11 September 2023

Declarations

:

: The Institutional Review Board of National Yang Ming Chiao Tung University, Taiwan (IRB), approved this study (YM111012E). The IRB agreed to waive the consent to participate requirement for this research because this research is low risk. Furthermore, the possible risk to the research subjects was no more than that of those who did not participate in the research, and the exemption from obtaining prior consent did not affect the rights or interests of the research subjects.

: Consent to publish is not required because the IRB agreed that this research did not require consent to participate.

: Nai-Jung Chiang has received payment for lectures from TTY Biopharm Company Limited, Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, PharmaEngine, Inc., and ACT Genomics Co., Ltd. Zi-Rong Chen, Chen-Han Chueh, and Yi-Wen Tsai declare that they have no conflicts of interest. This research was independently originated and conducted by the authors.

Document is current

Any future updates will be listed below